EP0726957B1 - ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE - Google Patents

ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE Download PDF

Info

Publication number
EP0726957B1
EP0726957B1 EP94927937A EP94927937A EP0726957B1 EP 0726957 B1 EP0726957 B1 EP 0726957B1 EP 94927937 A EP94927937 A EP 94927937A EP 94927937 A EP94927937 A EP 94927937A EP 0726957 B1 EP0726957 B1 EP 0726957B1
Authority
EP
European Patent Office
Prior art keywords
dnase
enzyme
pyogenes
dna
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP94927937A
Other languages
German (de)
English (en)
Other versions
EP0726957A1 (fr
Inventor
Craig W. Adams
Patty P.Y. Pang
Marina C. Belei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckman Coulter Inc
Original Assignee
Beckman Coulter Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckman Coulter Inc filed Critical Beckman Coulter Inc
Publication of EP0726957A1 publication Critical patent/EP0726957A1/fr
Application granted granted Critical
Publication of EP0726957B1 publication Critical patent/EP0726957B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Definitions

  • This invention is directed to recombinant DNase B derived from the pathogenic bacterium Streptococcus pyogenes , methods for its production, and methods for its use.
  • S. pyogenes a number of bacterial pathogens remain serious problems in medical practice and continue to cause severe, even fatal disease.
  • S. pyogenes a number of bacterial pathogens remain serious problems in medical practice and continue to cause severe, even fatal disease.
  • S. pyogenes a number of bacterial pathogens remain serious problems in medical practice and continue to cause severe, even fatal disease.
  • S. pyogenes Among the diseases caused by S. pyogenes are streptococcal pharyngitis ("strep throat"), scarlet fever, and their suppurative complications, including cervical adenitis, otitis media, mastoiditis, peritonsillar abscesses, meningitis, pneumonitis, pneumonia, puerperal sepsis, cellulitis of the skin, impetigo, lymphangitis, erysipelas, acute glomerulonephritis, and rheumatic fever
  • Such infections often occur in hospitals (nosocomial infection), particularly in patients whose normal immune system functioning is suppressed.
  • the latter category includes patients with AIDS, patients taking immunosuppressive drugs for cancer or to prevent transplant rejection, and patients having poor circulation, e.g., patients with diabetes.
  • S. pyogenes a DNA-degrading enzyme produced by S. pyogenes .
  • This enzyme which is excreted from S. pyogenes during infection, initiates development of substantial titers of antibody in patients who go on to develop acute rheumatic fever and acute glomerulonephritis.
  • the commercially-available tests fall into three categories: (1) a DNase B inhibition-based assay using the ability of the antibody to inhibit enzymatic activity; (2) a latex agglutination assay for antibody against a variety of S. pyogenes antigens; and (3) a turbidimetric inhibition assay.
  • ELISA assays have also been used in the research laboratory, but, as detailed below, they have not yet proven suitable for routine clinical application.
  • the DNase B inhibition assay is very slow, and typically requires about 4-8 hours to perform. Thus, in situations in which confirmation of anti-DNase B antibody is required rapidly so the treatment can be started as soon as possible should the presence of S. pyogenes be confirmed, the enzyme inhibition assay is not particularly useful.
  • the latex agglutination assay is designed to detect antibodies to five S. pyogenes antigens.
  • test results indicate poor agreement between the latex agglutination assay and a specific anti-DNase B tests.
  • G.C. Klein & W. L. Jones "Comparison of the Streptozyme Test with the Antistreptolysin O, Antideoxyribonuclease B, and Antihyaluronidase Tests," App. Microbiol. 21:257-259 (1971)
  • 12 out of 80 patients that tested negatively in the latex agglutination assay were, in fact, positive for anti-DNase B antibody. This high level of false negative results means that the test is undesirable for clinical use.
  • the turbidimetric inhibition assay depends on the inhibition of agglutination of latex particles coated with anti-DNase B antibody by a limiting quantity of a crude preparation of DNase B in the presence of serum containing anti-DNase B antibody, which competes for the antibody on the latex particles.
  • This assay which is described in U.S. Patent No. 5,055,395, incorporated herein by this reference, is relatively insensitive. Therefore, it is not suitable for use in the early stages of S. pyogenes infection, and it is precisely this period when accurate detection of the anti-DNase B antibody is most important. Additionally, the reagents used in the turbidimetric inhibition assay are difficult to manufacture.
  • an improved, rapid, and specific assay for anti-DNase B antibody Preferably, such an assay would be usable by a physician in his office and would require minimal equipment. This is because patients with diseases such as strep throat or scarlet fever typically see their family physician prior to hospitalization, and accurate diagnosis of S. pyogenes infection at that point would be preferable co a subsequent diagnosis made only when the patient has been hospitalized.
  • Another aspect of the invention is expression vectors for Streptococcus pyogenes DNase B enzyme comprising the DNA sequence described above operatively linked to at least one control sequence compatible with a suitable bacterial host cell.
  • the expression vector is a plasmid vector.
  • the DNA encoding the Streptococcus pyogenes DNase B enzyme is linked to at least one sequence from bacteriophage ⁇ .
  • Another aspect of the invention is a bacterial host cell transformed, transfected, or infected with an expression vector according to the present invention in a manner allowing the transformed bacterial host cell to express the Streptococcus pyogenes DNase B encoded by the DNA incorporated within the expression vector in a detectable quantity.
  • the expressed S. pyogenes DNase B can be either excreted or not excreted by the whole cell producing the enzyme, and can be in a soluble or an insoluble form.
  • Yet another aspect of the invention is a process for producing substantially purified Streptococcus pyogenes DNase B enzyme comprising:
  • Yet another aspect of the invention is the transcriptional fusion comprising the Streptococcus pyogenes DNase B recombinant DNA sequence according to the present invention fused with another gene, with the fusion having a detectable property altered from the property of the sequence according to the present invention or from the property of the protein encoded by the sequence according to the present invention, the altered property being selected from the group consisting of : (1) high level RNA expression; (2) high level protein expression (3) a second functional enzyme, receptor, or other active protein in the fusion; (4) fusion of the DNase B to an affinity ligand; (5) the production of a higher molecular weight protein; and (6) increased immunoreactivity.
  • a further aspect of the invention is a translational fusion comprising the protein encoded for by the Streptococcus pyogenes DNase B recombinant DNA sequence according to the present invention fused with another protein, with the fusion having a detectable property altered from the property of the protein encoded by the DNA sequence according to the present invention, the altered property being selected from: (1) high level RNA expression; (2) high level protein expression; (3) a second functional enzyme, receptor, or other active protein in the fusion; (4) fusion of the DNase B to an affinity ligand; (5) the production of a higher molecular weight protein; and (6) increased immunoreactivity. the enzymes of the two fractions.
  • Another aspect of the invention is a method for detecting and/or determining anti - Streptococcus pyogenes DNase B antibody in a test sample.
  • the method comprises the steps of:
  • An alternative method for detecting anti-DNase B antibody comprises the steps of:
  • This approach can be used for nephelometric, turbidimetric, agglutination, or ELISA methods of quantitation.
  • An alternative method for detecting S. pyogenes DNase B antibody comprises:
  • Another alternative method for detecting anti-DNase B antibody is capillary electrophoresis.
  • Another aspect of the invention is a vaccine for immunising a mammal against infection with S. pyogenes comprising a quantity of purified S. pyogenes DNase B enzyme sufficient to stimulate the production of antibodies specific for S. pyogenes DNase B, wherein the purified S. pyogenes DNase B enzyme is encoded by the DNA sequence of the present invention.
  • a further aspect of the invention is a vaccine for immunising a mammal against infection with S. pyogenes comprising a quantity of purified S. pyogenes DNase B enzyme sufficient to stimulate the production of antibodies specific for S. pyogenes DNase B, wherein the purified S. pyogenes DNase B enzyme is that which is obtainable by
  • a yet further aspect of the invention is a vaccine for immunising a mammal against infection with S. pyogenes comprising a quantity of purified S. pyogenes DNase B sufficient to stimulate the production of antibodies specific for S. pyogenes DNase B wherein the purified S. pyogenes DNase B enzyme is the protein obtainable by use of the genetic construct of the present invention in an appropriate expression vector.
  • Another aspect of the present invention is a medication comprising an enzymatically active DNase B enzyme and means for generating an aerosol containing the enzymatically active DNase B enzyme, for use in treating cystic fibrosis in a patient with cystic fibrosis comprising delivery of said aerosol in a quantity sufficient to reduce lung fluid viscosity in the patient wherein the purified S. pyogenes DNase B enzyme is encoded by the DNA sequence of the present invention.
  • a further aspect of the present invention medication comprising an enzymatically active DNase B enzyme and means for generating an aerosol containing the enzymatically active DNase B enzyme, for use in treating cystic fibrosis in a patient with cystic fibrosis comprising delivery of said aerosol in a quantity sufficient to reduce lung fluid viscosity in the patient wherein the purified S. pyogenes DNase B enzyme is that which is obtainable by
  • the cloning and expression of the Streptococcus pyogenes DNase B gene in E. coli requires the following steps, which are optimized carefully to achieve cloning of the intact gene in a form in which active enzyme is expressed from the gene:
  • Genomic DNA is preferably isolated from S. pyogenes under conditions minimizing activity of endogenous nucleases as well as other factors that can degrade or denature DNA. This requires cell lysis and degradation of protein.
  • a preferable method for lysing cells is incubation with the proteolytic enzyme achromopeptidase at 65°C, followed by incubation with the chaotropic detergent sodium dodecyl sulfate (SDS). This procedure is most preferably carried out in the presence of a chelating agent such as EDTA.
  • SDS sodium dodecyl sulfate
  • proteases such as pronase and proteinase K can be used to lyse the cells.
  • Other lysis procedures are known in the art. (S.
  • DNA is then extracted with phenol or phenol-chloroform and the extracted DNA is precipitated with ethanol.
  • a suitable extraction sequence is two extractions with an equal volume of phenol, followed by one extraction with a 1:1 mixture of phenol/chloroform (Example 1).
  • the extraction buffer preferably contains a chelating agent such as EDTA to minimize nuclease activity.
  • EDTA chelating agent
  • a suitable source of DNA is strain ATCC No. 14289 of S. pyogenes , also known as C203S, a non-M containing variant of strain C203.
  • C203S a non-M containing variant of strain C203.
  • similar techniques could be used for other strains of S. pyogenes that contain the gene for DNase B.
  • the isolated DNA is treated with RNase A after extraction and ethanol precipitation, then further purified in a cesium chloride gradient.
  • the isolated genomic DNA is preferably fragmented before cloning. Most preferably, fragmentation is performed by passing the DNA through a syringe needle, most preferably a 25-gauge syringe needle, about 300 times. This results in sheared DNA having an average size of approximately 6-8 kb.
  • partial digestion with a restriction endonuclease can be used, such as Sau 3A or Mbo I. This is described, for example, in A.-M. Frischholz, "Digestion of DNA: Size Fractionation,” Meth. Enzymol. 152:183-189 (1987), incorporated herein by this reference.
  • Such a cloning vector typically comprises the DNA sequence coding for S. pyogenes DNase B operatively linked to at least one control sequence compatible with a suitable bacterial host cell.
  • control sequences include operators and promoters.
  • Suitable promoters include bacteriophage ⁇ p L promoter, a hybrid trp-lac promoter, and bacteriophage T7 promoter.
  • the cloning vector preferably also comprises a suitable ribosome-binding site for expression.
  • a preferred cloning vector is ⁇ gt11 (R. A. Young and R. W. Davis, Proc. Natl. Acad. Sci.
  • Eco RI linkers can be ligated to ⁇ gt11 arms after digestion with Eco RI restriction endonuclease.
  • the internal Eco RI sites are blocked by the use of Eco RI methylase, as the restriction endonuclease does not digest DNA methylated at the adenine residues in the recognition site by the methylase.
  • the DNA is packaged into bacteriophage ⁇ heads in vitro using a mixture of extracts prepared from bacteria infected with bacteriophage ⁇ mutants in genes required for assembly of phage particles.
  • Packaging procedures are well-known in the art and are described, e.g. in Sambrook et al., supra , vol. 1, pp. 2.95-2.108.
  • the phage particles assembled by in vitro packaging are used to infect susceptible E. coli bacteria.
  • a particularly preferred strain of bacterial host cells is Y1090 (-pMC9), that is, lacking the pMC9 plasmid.
  • a suitable method is to overlay the plaques with a top agar overlay of DNase test agar (Difco, Detroit, Michigan) containing 0.01% toluidine blue O as a color indicator. This allows detection of plaques expressing the DNase B gene.
  • the unexpectedly high level of expression of the DNase B gene in this system allowed direct detection of positive clones by direct detection of the resulting enzymatic activity, without a need for immunological screening, which is commonly required for the detection of cloned gene products.
  • a process for producing substantially purified Streptococcus pyogenes DNase B enzyme using transfected host cells can comprise:
  • the ⁇ gt11 phage containing the S. pyogenes DNase B gene (designated 2-6) was isolated and DNA was prepared from the phage. This clone was analyzed by restriction analysis and the results are shown in Figure 1. Analysis of Eco RI and Eco RI/ Sac I subclones for the presence of nuclease activity indicates that part of the DNase B gene was located within the internal Sac I to the Eco RI region, as shown in Figure 2.
  • Sequencing of the cloned DNA can be performed using standard techniques, e.g. the Sanger dideoxynucleotide chain termination method. Sequence analysis can be initiated by priming synthesis within the ⁇ gt11 phage across the suspected region of DNase activity. Results of such sequencing are shown in Figure 3.
  • the cloned DNA whose sequence is shown in Figure 3 incorporates a lengthy open reading frame (ORF).
  • ORF open reading frame
  • the amino acid sequence derived from translation of this ORF is shown in Figures 3 and 4.
  • the amino acid sequence of the 5'-terminal portion of this ORF starting at amino acid 44 (Gln) is consistent with the amino acid sequence derived by sequencing purified naturally occurring S. pyogenes DNase B (Section IV).
  • the DNA comprises substantially purified DNA comprising DNA encoding an amino acid sequence selected from the group consisting of the amino acid sequence of: (i) Streptococcus pyogenes DNase B enzyme as shown in Figure 4; and (ii) a sequence encoding a functional equivalent of S. pyogenes DNase B enzyme.
  • the DNA is substantially free of DNA that does not encode the amino acid sequence of Figure 4 or a functional equivalent of S. pyogenes DNase B enzyme except for a leader peptide fused to the amino terminus of S. pyogenes DNase B enzyme.
  • the translation product produced from the open reading frame includes a leader peptide.
  • the term “functional equivalent” refers to a protein possessing DNase activity detectable in the generally used assays for S. pyogenes DNase B and cross-reacting to at least a detectable extent with antibodies against substantially purified DNase B.
  • the term “functional equivalent” includes, but is not limited to, proteins whose sequence differs from the sequence of Figure 4 by one or more conservative amino acid substitutions.
  • Such conservative amino acid substitutions include, but are not limited to, substituting any of isoleucine (I), valine (V), and leucine (L) for any other of these amino acids; aspartic acid (D) for glutamic acid (E) and vice versa; glutamine (Q) for asparagine (N) and vice versa; and serine (S) for threonine (T) and vice versa.
  • the above-mentioned substitutions are not the only amino acid substitutions that can be considered "conservative.”
  • Other substitutions can also be considered conservative, depending on the environment of the particular amino acid. For example, glycine (G) and alanine (A) can frequently be interchangeable, as can be alanine and valine (V).
  • Methionine (M) which is relatively hydrophobic, can frequently be interchanged with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are frequently interchangeable in locations in which the significant feature of the amino acid residue is its charge and the differing pK's of these two amino acid residues are not significant. Still other changes can be considered "conservative" in particular environments.
  • the DNA may also include DNA sequences comprising a portion of the sequence of Figure 3 of sufficient size and specificity to serve as a reactant in a reaction requiring specific base hybridization.
  • a DNA sequence can be a primer for an amplification reaction such as the polymerase chain reaction (PCR), ligase chain reaction (LCR), or other amplification reaction.
  • the DNA sequence can be a hybridization probe.
  • the DNA sequence may be at least 10 bases long; or the sequence is at least 50 bases long.
  • the cloned gene for S. pyogenes DNase B can be transferred to the E. coli expression plasmid ⁇ 33, which expresses the cloned gene under the control of the bacteriophage ⁇ promoter pL.
  • the S. pyogenes DNase B gene is preferably inserted into the expression plasmid by using PCR to attach modified ends to the DNase B gene from the ⁇ 2-6 clone.
  • the following nucleotides can be used as primers for the PCR reaction following standard PCR procedures with Thermus aquaticus DNA polymerase:
  • primers can be used with the ⁇ gt 11 DNase B clone 2-6 DNA as a template for amplification.
  • the resulting amplification products can be digested with the endonuclease Bam HI and Sal I prior to insertion into the ⁇ 33 expression vector. This creates a translational fusion regulated by the pL promoter.
  • a suitable strain of E. coli (C600C1 + , gal K -) is transformed with the inserted DNA, and bacteria containing the plasma can be selected by selection with ampicillin. DNA can be prepared from these colonies by standard minipreparation techniques, e.g., those described in F.M.
  • Plasmids of the desired construction can be introduced into an E. coli host strain that is subject to induction by the nalidixic acid protocol, as described in J. E. Mott et al., "Maximizing Gene Expression from Plasmid Vectors Containing the ⁇ pL Promoter: Strategies for Overproducing Transcription Termination Factor ⁇ ," Proc. Natl. Acad. Sci.
  • the recombinantly produced enzyme from ⁇ 2-6 phage contains a leader peptide fused to the amino terminus of the DNase.
  • This leader peptide has the sequence M-N-L-L-G-S-R-R-V-F-S-K-K-C-R-L-V-K-F-S-M-V-A-L-V-S-A-T-M-A-V-T-T-V-T-L-E-N-T-A-L-A-R (SEQ ID NO: 1).
  • Immunoinhibition assays demonstrate that recombinant S. pyogenes DNase B is inhibited by anti-DNase enzyme in human serum in a manner identical to non-recombinant DNase B enzyme, based on the ability of the DNase to use a DNA-dye complex as substrate.
  • Mutants or variants of the S. pyogenes DNase B gene may have altered DNase B activity.
  • Such mutant DNase B enzymes may have higher or lower levels of nuclease activity, and these mutants may include mutants of the protein whose amino acid sequence is shown in Figure 4 in which at least one of the following mutations occurs:
  • mutant DNase B proteins encoded by mutant DNase B genes can be used for their nuclease activity or for their immunogenicity.
  • these mutants when used for their immunogenicity, contain single amino acid changes which remove all nuclease activity, but maintain all significant immune epitopes, so that they substantially retain the antigenic reactivity of natural S. pyogenes DNase B enzyme.
  • high level expression in E. coli can be achieved without altering human antibody reactivity with the altered DNase B.
  • Such mutants or variants can be prepared according to techniques well-known in the art, such as those described in Sambrook et al., supra , Ch.
  • Such technique include linker-insertion mutagenesis, linker-scanning mutagenesis, oligonucleotide-mediated mutagenesis with the polymerase chain reaction (PCR) technique, and growth in highly mutagenic strains.
  • PCR polymerase chain reaction
  • mutant proteins When used for their nuclease activity, the mutant proteins will typically be functional equivalents of the recombinant DNase enzyme of Figure 4, as that term is defined above, but are not necessarily limited thereto.
  • the leader peptide for DNase B with an amino acid sequence of M-N-L-L-G-S-R-R-V-F-S-K-K-C-R-L-V-K-F-S-M-V-A-L-V-S-A-T-M-A-V-T-T-V-T-L-E-N-T-A-L-A-R (SEQ ID NO: 1), can be used for expression and production of recombinant proteins in bacteria.
  • a suitable process for the use of the leader peptide comprises:
  • the bacterium can be Escherichia coli or, alternatively, a gram-positive bacterium such as Staphylococcus , Streptococcus , and Streptomyces .
  • the recombinant protein is excreted by the prokaryote into its culture medium so that it can be recovered from the culture medium.
  • Methods for fusing the DNA segment coding for leader peptide to the gene for the protein to be produced are well-known in the art and include blunt-end ligation. Blunt-end ligation is typically performed with T4 ligase (V. Sgaramella & H.G. Khorana, "Studies on Polynucleotides. CXII. Total Synthesis of the Structural Gene for an Alanine Transfer RNA from Yeast. Enzymic Joining of the Chemically Synthesized Polydeoxynucleotides to Form the DNA Duplex Representing Nucleotide Sequence 1 to 20," J. Mol. Biol. 72:427 (1972); V. Sgaramella & S.D.
  • Ehrlich "Use of the T4 Polynucleotide Ligase in the Joining of Flush-Ended DNA Segments Generated by Restriction Endonucleases, " Eur. J. Biochem. 86:531 (1978)), and is preferably performed in the presence of condensing agents such as polyethylene glycol or hexamminecobalt chloride.
  • restriction endonuclease can be used to generate cohesive ends for ligation.
  • This procedure uses polyacrylamide gel analysis of the DNase B found in the commercial assay reagent and a comparison to the behavior on gel electrophoresis of the natural enzyme.
  • the purification procedure employs the following steps, starting with a crude extract or other source of the enzyme: (1) absorption to and elution from diethylaminoethyl cellulose to produce a first eluate; (2) chromatography of the first eluate on phenyl agarose to produce a second eluate; (3) chromatography of the second eluate on heparin agarose to produce a third eluate; and (4) chromatofocusing of the third eluate to produce substantially purified DNase B enzyme.
  • the chromatofocusing is preferably carried out on a mono-P column.
  • the purified DNase is further fractionated to remove ampholytes used during chromatofocusing using reverse-phase high-pressure liquid chromatography on C4 with a gradient of 0.1% trifluoroacetic acid in water and 0.08% trifluoroacetic acid in acetonitrile.
  • the purification procedure results in substantially purified Streptococcus pyogenes DNase B enzyme substantially free of proteins other than Streptococcus DNase B enzyme and Streptococcus DNase B enzyme fused at its amino terminus with a leader peptide.
  • the substantially purified protein is substantially free of mitogenic activity (See Example 6 below).
  • Fraction I which elutes from the chromatofocusing column at pH 8.55-8.4
  • Fraction II which elutes from the chromatofocusing column at pH 8.22-8.13.
  • Molecular weight data obtained from mass spectroscopy indicates that the difference in molecular weights between Fractions I and II of the purified natural DNase B is consistent with a minor modification of an otherwise identical amino acid sequence. A possible modification is deamination, which would cause the appropriate pI shift.
  • the purified protein can be sequenced.
  • the first 23 amino acids of both fraction I and II produced the following readable sequence: Q-T-Q-V-S-N-D-V-V-L-N-D-G-A-S-X-Y-L-N-E-A-L-A (SEQ ID NO: 4), where X represents tryptophan or lysine.
  • this sequence represents a means for designing probes suitable for hybridizing with at least a DNA sequence coding for the amino-terminal amino acid sequence of the gene.
  • Recombinant S. pyogenes DNase B which is present at a high level in the chimeric cells, can be purified by similar techniques.
  • the recombinant DNase B can be purified from phage lysate collected from E. coli infected with ⁇ DNase B 2-6 phage by chromatography on Q-sepharose (trimethylaminomethyl agarose), ammonium sulfate precipitation, chromatography on heparin sepharose, and chromatography on Q-sepharose.
  • Q-sepharose trimethylaminomethyl agarose
  • ammonium sulfate precipitation chromatography on heparin sepharose
  • Q-sepharose trimethylaminomethyl agarose
  • the recombinant DNase B produced in E. coli transfected with recombinant plasmid ⁇ 33 expressing S.
  • pyogenes DNase B from the pL promoter can be purified by chromatography on heparin sepharose, chromatography on Q-sepharose, and reverse phase high pressure liquid chromatography. Other purification methods are known and can be used by one skilled in the art.
  • nucleic acid probe hybridizing with the DNA sequence coding for the amino-terminal 23 amino acids of the S. pyogenes DNase B enzyme with no greater than about a 30% mismatch.
  • the nucleic acid probe can be RNA or DNA.
  • the degree of mismatching is no greater than about 10% under standard stringent conditions, i.e., those described in F. Ausubel et al., in Current Protocols in Molecular Biology (Wiley-Interscience, New York, 1990).
  • Suitable sequences of such probes can be derived by using the codon usage table for enteric bacterial genes given for the relevant amino acids in Table 1.
  • CODON USAGE FOR AMINO ACIDS IN AMINO-TERMINAL REGION OF S. PYOGENES DNASE Gln (O) Thr (T) Codon Frequency Codon Frequency CAG 0.86 ACC 0.55 CAA 0.14 ACU 0.35 ACG 0.07 ACA 0.04 Val (V) Ser (S) Codon Frequency Codon Frequency GUU 0.51 UCC 0.37 GUA 0.26 UCU 0.34 GUG 0.16 AGC 0.20 GUC 0.07 UCG 0.04 AGU 0.03 UCA 0.02 Asn (N) Asp (D) Codon Frequency Codon Frequency ACC 0.94 GAC 0.67 AAU 0.06 GAU 0.33 Leu (L) Gly (G) Codon Frequency Codon Frequency CUG 0.83 GGU 0.59 CUC 0.07 GGC 0.38 CUU 0.04 GGG 0.02
  • R represents a purine (i.e., A or G)
  • Y represents a pyrimidine (T or C)
  • S represents G or C
  • W represents A or T
  • N represents any of the four common deoxyribonucleotides (i.e., A, G, C, or T).
  • This probe, and other probes can be synthesized by procedures well-known in the art, such as solid-phase DNA synthesis by the phosphotriester or phosphite triester methods, as disclosed, e.g., in "Nucleic Acids in Chemistry and Biology” (G. M. Blackburn & M. J. Gait, eds., IRL Press, Oxford, 1990), ch. 3. pp. 106-123.
  • the promoter sequence is retained in the ⁇ 2-6 clone. This sequence includes a start site for transcription and sites substantially homologous to the consensus -10 and -35 sites for bacterial promoters (Example 9).
  • a method of using this promoter sequence for expressing a protein other than DNase B comprises:
  • the protein can be expressed in S. pyogenes or in a prokaryote other than S. pyogenes , such as E. coli.
  • the promoter can be incorporated in a vector or a plasmid for expression of a gene operatively linked to the promoter in the vector or plasmid.
  • the present invention also encompasses several uses of the substantially purified S. pyogenes DNase B enzyme, whether purified from natural sources or produced by recombinant DNA techniques.
  • the antibodies can either be polyclonal or monoclonal. Preparation of both polyclonal and monoclonal antibodies is described in E. Harlow and D. Lane, “Antibodies: A Laboratory Manual” (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1988). pp. 53-318. The resulting antibodies can be used for detection of the S. pyogenes enzyme, i.e., in suspected cultures.
  • An important use for the substantially purified S. pyogenes DNase B enzyme of the present invention is the detection of anti- S. pyogenes DNase B antibodies, such as in serum. As described above, the presence of such antibodies is indicative of active S. pyogenes infection and a warning signal that serious suppurative sequelae may occur.
  • One method of detecting the anti-DNase B antibody employs the fact that the antibody is capable of inhibiting the activity of the enzyme. Such a method can comprise the following steps:
  • the enzyme assay can be performed by standard methods, such as the DNA-dye complex degradation assay of Wampole Laboratories (Cranbury, NJ). This assay is based on the ability on the DNase to use a DNA-dye complex as substrate. This complex exhibits a maximum absorption wavelength of 642 nm. However, as the DNA-dye complex is degraded by the DNAse, there is a shift in the maximum absorption wavelength and a decrease in the absorption at 642 nanometers.
  • Other enzymatic assays are available, such as viscosimetric assays, which measure the ability of the enzyme to depolymerize long DNA molecules, thus greatly reducing the viscosity of solutions containing DNA.
  • assays can be performed by using radioactive DNA as a substrate and quantitating the release of radioactivity after incubation. Other methods for the assay of deoxyribonuclease are well known in the art.
  • An alternative assay for anti-DNase B enzyme antibody in serum is an ELISA assay. This assay comprises:
  • the solid support used is typically plastic, such as polystyrene, but other solid supports, such as nitrocellulose, can also be used.
  • the detection of the bound antibody is typically performed by adding a second antibody specific for the first antibody; the second antibody does not bind the S. pyogenes DNase B enzyme.
  • Such an antibody can be, for example, enzyme-labeled anti-human immunoglobulin G.
  • the enzyme label is typically alkaline phosphatase, ⁇ -galactosidase, glucose oxidase, or horseradish peroxidase. Such enzymes give products that have optical absorption in the visible spectrum, and can be detected either visually or with a spectrophotometer.
  • antigen-antibody complexes can also be used to assay anti-DNase B antibody in serum. These techniques detect an aggregated antigen-antibody complex, here an enzyme-antibody complex, by a change in light absorption or scattering.
  • an assay comprises:
  • the DNase B can be attached to higher molecular weight carriers, such as latex polymers, plastic or gel beads, and the like.
  • the enzyme In a number of applications, it is particularly advantageous to attach the enzyme to latex particles. This can provide several advantages, including stabilization of the enzyme and increased sensitivity of detection, either by turbidimetry or nephelometry.
  • the latex agglutination assay format is popular for clinical immunoassays.
  • DNase B can be used to latex particles. Some of the widely used methods are: (1) attachment by adsorption to latex particles; (2) attachment by covalent coupling via carboxyl groups on the latex particles; and (3) attachment by covalent coupling via aldehyde groups on the latex particles.
  • the size of the latex particles used for attachment can range from about 15 nm to about 1000 nm in diameter, depending on the application.
  • the reaction between the DNAse B and the anti-DNase B can be detected by nephelometry or turbidimetry.
  • Another alternative method for detecting anti-DNase B antibody is capillary electrophoresis.
  • the recombinant protein can be used for vaccine development to immunize against S. pyogenes in susceptible individuals, and also can be used as an aerosol in the treatment of lung viscosity symptoms in diseases such as cystic fibrosis when the viscosity is due to exudates containing high concentrations of DNA.
  • a quantity of a purified S. pyogenes DNase B enzyme according to the present invention is administered to a mammal.
  • the quantity is sufficient to stimulate production of antibodies specific for S. pyogenes DNase B.
  • Administration is typically by injection, and can be intravenous, intramuscular, subcutaneous, intradermal, or by other routes.
  • the DNase B enzyme can be administered with an adjuvant to increase the immune response.
  • Suitable adjuvants are well known in the art and include complete and incomplete Freund's adjuvant, as well as aluminum hydroxide with or without heat-killed Bordetella pertussis bacteria.
  • the enzyme can be aggregated, precipitated, or coupled to insoluble matrices.
  • One particularly suitable enzyme according to the present invention for use in immunization is a mutant enzyme in which the DNase activity is completely or substantially eliminated and the antigenicity is wholly or substantially retained.
  • a method of use of enzymatically active DNase B enzyme can comprise:
  • Administration of the aerosol can be performed using inhaler devices well-known in the art and frequently used to deliver steroids and other drugs to the respiratory tract by inhalation.
  • the S. pyogenes DNase B gene was identified by an activity based colorimetric detection of nuclease activity produced from a recombinant ⁇ bacteriophage.
  • the phage was a product of a ⁇ library containing sheared DNA purified from S. pyogenes (Lancefield Group ATCC No. 14289) genomic DNA.
  • S. pyogenes strain ATCC 14289 was streaked onto Todd Hewitt agar plates and incubated at 37°C for two days. A single colony was used to inoculate one liter of Todd Hewitt broth with 10% calf serum. The culture was allowed to grow to high density at 37°C with shaking for about 36 hours.
  • the cells were collected by centrifugation in a Beckman J6 centrifuge at 3500 rpm at 4°C for 45 minutes.
  • the cell pellet was resuspended in 25 ml of 40 mM Tris, pH 7.5, 1 mM EDTA.
  • the mixture was extracted twice with an equal volume of phenol, followed by one extraction with phenol/chloroform (1:1).
  • the DNA in the aqueous phase was precipitated by ethanol.
  • the DNA was recovered by centrifugation.
  • the pellet was resuspended in 4 ml of 10 mM Tris-HCl, pH 7.5, 1 mM EDTA (TE).
  • RNase A 50 ⁇ l at 10 mg/ml was added and the mixture was incubated at 37°C for three hours.
  • the DNA was further purified in a cesium chloride gradient.
  • the final concentration of DNA was about 0.5 mg/ml.
  • the isolated chromosomal DNA (300 ⁇ ml) was added to 200 ⁇ l of TE buffer. The mixture was passed through a 1 ml syringe with a 25-gauge needle about 300 times to shear the DNA to an average size of 6 kb.
  • the sheared DNA (150 ⁇ l) was treated with E. coli ligase to repair existing nicks in the DNA which might otherwise have become gaps with subsequent manipulations.
  • E. coli ligase To 150 ⁇ l of DNA was added 20 ⁇ l of 10 x E. coli ligase buffer (0.5 M Tris-HCl, pH 7.6, 100 mM MgCl 2 , 100 mM dithiothreitol, and 500 ⁇ g/ml bovine serum albumin), 20 ⁇ l of NAD + (36 mM) and 7 ⁇ l of E. coli ligase (New England Biolabs, Beverly, Mass., 4 units/ ⁇ l) was added to the DNA and the mixture was left at room temperature for four to five hours. The ligase was heat killed at 65°C for 15 minutes. The DNA was precipitated by ethanol.
  • Eco RI sites in the ligase-treated DNA were methylated with Eco methylase following the protocol of the manufacturer (Promega, Madison, Wis.). This was done to block internal Eco RI sites whose cleavage would interfere with the cloning procedure.
  • the sheared ends of the DNA were repaired with T4 DNA polymerase by adding 30 ⁇ l of 0.1 M MgCl 2 , 20 ⁇ l of 2.5 mM of each of the four deoxyribonucleoside triphosphates, and 2 ⁇ l of T4 DNA polymerase (3000 U/ml) to the DNA mix after methylation. The reaction was carried out for 15 minutes at room temperature. The mixture was extracted once with phenol/chloroform and then with ether. The DNA in the aqueous fraction was then precipitated with ethanol.
  • Eco RI linkers were ligated onto the DNA.
  • the linkers used were octamers from New England Biolabs. After linker ligation, the DNA was digested with an excess of Eco RI restriction endonuclease enzyme. DNA of the desired size range, namely 6-8 kb, was purified from an agarose gel after electrophoresis. The DNA was concentrated by ethanol precipitation and was then ready for ligation into ⁇ gt11.
  • Approximately 2 ⁇ g of sheared DNA was ligated with 1 ⁇ g of ⁇ gt11 arms previously digested with Eco RI restriction endonuclease and in which the terminal phosphate residue had been removed by treatment with alkaline phosphatase.
  • the ligation was carried out with bacteriophage T4 ligase in a total volume of 5 ⁇ l. The ligation reaction was performed at 4°C overnight.
  • the entire ligation mix was packaged in vitro using the Promega (Madison, Wis.) packaging extract.
  • One ⁇ l of packaged phage was plated on a lawn of Y 1090 E. coli in the presence of isopropylthio- ⁇ -D galactoside (IPTG) and the chromogenic substrate 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside) (Xga1) approximately 5% of the plaques were blue.
  • IPTG isopropylthio- ⁇ -D galactoside
  • Xga1 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside
  • the non-amplified library (10 ⁇ l) was plated with 0.1 ml of an overnight culture of LE 392. After five hours, the plates were overlaid with 0.5 x BBL DNase test agar plus 0.01% toluidine blue plus 10 mM MgCl2. A total of 10 plates was screened. Forty-four pink plaques (potentially nuclease positive) were rescreened. Nine of the 44 pink plaques consistently rescreened as positive for nuclease activity.
  • E. coli strain Y1090 without the plasmid pMC9 was used as the host for nuclease carrying phage.
  • Plate lysates were used to generate stocks to plaque purify the clones.
  • the host and phage were plated directly on 0.5 x BBL DNase test agar plus 0.01% toluidine blue plus 10 mM MgCl 2 directly instead of overlaying after five hours of incubation. Lysates of the nine recombinant clones were analyzed on SDS-polyacrylamide gels containing DNA. The nuclease in all nine clones retained their activity after SDS denaturation and all have the same apparent molecular weight, approximately 25 kd.
  • one phage showing DNase activity designated as 2-6 was analyzed further.
  • the ⁇ DNase 2-6 clone was analyzed with restriction endonuclease analysis to characterize the DNA fragment.
  • the S. pyogenes genomic insert in the ⁇ vector in the 2-6 clone was approximately 5.2 kb.
  • the location of the nuclease gene was determined by subcloning smaller regions of the DNase 2-6 clone back into ⁇ gt 11 and testing the subclones for nuclease activity.
  • Figure 2 shows the location of the various subclones and their nuclease activity. Subclones 1 and 4 produced nuclease activity but were very unstable. Subclones 2 and 3 lacked nuclease activity but were stable.
  • the amino-terminal sequence from the DNase B protein was used in conjunction with the genetic code to generate a set of degenerate oligonucleotides that was used to hybridize to the DNase 2-6 insert and some of the subclones. These oligonucleotides hybridized to the 3.5 kb Eco RI fragment in DNase B 2-6 and the Sac I/ Eco RI fragment in subclone 3.
  • Nucleotide sequence analysis was performed on clone 2-6 by the dideoxynucleotide chain termination method of Sanger et al., supra . Sequence analysis was initiated by priming synthesis from within the ⁇ gt11 phage of clone 2-6 across the suspected region of DNase activity. The results of sequencing are shown in Figure 3. The S. pyogenes DNase B is within the first full open reading frame of the sequence.
  • Native S. pyogenes DNase B was purified using a commercial DNase B assay reagent as a marker of the correct nuclease.
  • polyacrylamide gel electrophoresis results obtained with the DNase B in the commercial kit was compared to the results from gel electrophoresis in extracts produced from S. pyogenes ATCC No. 14289.
  • the purification procedure included: batch absorption on DE-23 diethylaminoethyl cellulose (Whatman) (2) chromatography on phenyl Sepharose® (Pharmacia, Uppsala, Sweden); (3) chromatography on heparin Sepharose® (Pharmacia); and (4) mono-P chromatofocusing (Pharmacia).
  • Streptococcus pyogenes ATCC NO. 14289 American Type Culture Collection, Rockville, Maryland
  • A. Bernheimer C203S non-M containing variant of C203
  • DNase B-containing culture media the enzyme being secreted into the culture media by the bacteria.
  • Volumes of brain heart infusion media (1 liter) (Difco Laboratories, Detroit, Michigan) supplemented with 0.01% washed goat red blood cells were inoculated with 1 ml of a fresh overnight culture. These cultures were grown for 20 hours with moderate agitation (300 rpm) at 37°C in 2 liter Erlenmeyer flasks.
  • the culture medium Prior to purification the culture medium was clarified and sterilized by filtration using a Pellicon filter (0.22 ⁇ m Durapore GVLP membrane) followed by filtration through an 0.45 ⁇ m disposable filtration apparatus (Nalgene, Nalge Co., Rochester, New York). Approximately 105 liters of culture media was processed with this procedure.
  • the clarified media was concentrated by ultrafiltration using the Pellicon apparatus and a 10 K membrane (PLGC, regenerated cellulose) with a filter area of about 0.46 m 2 at a flow rate of 120 ml/min, and a pressure of 20 lbs per square inch (1.4 Kg/cm 2) .
  • the initial volume of 105 liters of media was eventually concentrated to 4 liters with a protein concentration of 2.3 mg/ml.
  • Diethylaminoethyl cellulose (DEAE-cellulose) (DE23, Whatman, England) was regenerated by washing with 15 volumes of 0.5 M HCl followed by a second wash with 15 volumes of 0.5 M NaOH. After a repetition of the washing with sodium hydroxide, the DEAE-cellulose was washed with water until neutral. Finally, the cellulose was equilibrated overnight in TMC buffer (1 mM Tris, 1 mM MgCl, 1 mM CaCl 2 , pH 7.5).
  • the equilibrated wet cellulose (100 g) was added to 500 ml of concentrated S. pyogenes media supernatant. The mixture was shaken at 300 rpm for 20 minutes at 4°C prior to centrifugation at 3500 rpm for 45 minutes. The cellulose was washed with 450 ml of TMC buffer and the two supernatants were combined.
  • the 80-ml phenyl sepharose column was loaded at 1.85 ml/min with 1100 ml of sample at a concentration of 258 ⁇ g/ml.
  • the DNase activity was collected in the flow-through prior to concentration by ultrafiltration using a 10-kd membrane (Diaflo YM10, Amicon Division, W. R. Grace & Co.)
  • the final protein concentration was 0.245 mg/ml, in 55 ml.
  • the concentrated effluent from the phenyl-sepharose column was dialyzed against Heparin Buffer A (20 mM HEPES, pH 7.9, 2 mM dithiothreitol, 10 mM MgCl 2 , 0.2 mM EDTA, 0.1 NaCl, 10% glycerol).
  • Heparin Buffer A (20 mM HEPES, pH 7.9, 2 mM dithiothreitol, 10 mM MgCl 2 , 0.2 mM EDTA, 0.1 NaCl, 10% glycerol).
  • a heparin Sepharose CL-6B (Pharmacia) column 80 ml was equilibrated with the Heparin Buffer A prior to loading at a flow rate of 1.0 ml/min. After washing the column with three volumes of heparin buffer A, a gradient between 0% and 100% buffer B was run at a flow rate of 2.2 ml/min. Buffer B was
  • the concentrated DNase fraction was dialyzed against 25 mM diethanolamine, pH 9.5 prior to chromatofocusing.
  • the mono P 5/20 column (Pharmacia, Piscataway, N.J.) equilibrated in the loading buffer (25 nM ethanolamine, pH 9.5), was injected with 500 ⁇ l of sample and washed with 9 ml of loading buffer.
  • the column was eluted with 100% buffer B (10% polybuffer 96 (Pharmacia), pH 6.0). The total volume eluted was 34 ml; fractions of 0.5 ml were collected.
  • Fraction II Two peaks of activity were collected at pH 8.55-8.4 (fractions 25-29), designated herein as Fraction I, and 8.22-8.13 (fractions 34-35), designated herein as Fraction II.
  • the collected fractions were analyzed by isoelectric focusing activity gels, silver staining, and by SDS-polyacrylamide gel electrophoresis.
  • Peak fractions from the chromatofocusing column were further purified to remove the ampholytes used for chromatofocusing by reverse phase high pressure liquid chromatography using a C4 column (Beckman System Gold Instrument, Beckman Instruments, Fullerton, California). Samples were loaded in buffer A (0.1% trifluoroacetic acid in water) and a gradient of 0%-100% buffer B (0.8% trifluoroacetic acid in acetonitrile) was used to elute the column at a flow rate of 1 ml/min. Those proteins eluted in 65% buffer B in a volume of about 1 ml.
  • SDS-polyacrylamide gel analysis of all samples was performed using the PHAST System (Pharmacia LKB, Piscataway, New Jersey) automated instrument. SDS-polyacrylamide gel electrophoresis was performed on the PhastGel 10-15% gels. Isoelectric gels were run using the PhastGel IEF 3-9 gels. Silver staining of both the SDS and the isoelectric gels was performed using the PhastSystem automated staining device (Pharmacia LKB).
  • Activity assays of the DNase samples on the isoelectric focusing gels were performed by overlaying the gels after electrophoresis with 5 ml of a 1% melted agarose solution containing phosphate buffered salts and 1 ml of reconstituted DNase substrate dye (Wampole). Incubation of the IEF gels with the substrate overlay at room temperature resulted in the detection of activity by the conversion of the blue substrate dye to a pink color centered around the nuclease activity.
  • Activity assays of SDS-denatured samples were performed using an SDS-14% polyacrylamide gel that was polymerized in the presence of 500 ⁇ g/ml herring testes DNA.
  • the gels were rinsed with water and equilibrated with 40 mM Tris-HCl, pH 7.5, 2 mM MgCl 2 , 0.02% sodium azide for 2 hours at 37°C. Ethidium bromide was added to 1 ⁇ g/ml in order to observe the nuclease activity visible as a result of the degradation of the DNA by the nuclease.
  • Fractions I and II of the purified DNase were determined using an Applied Biosystems (Foster City, California) 477 sequenator. Samples of each of the purified enzymes (Fractions I and II) were loaded on to an Applied Biosystems (Foster City, CA) 470 Protein Sequencer. The first 23 amino acids of both Fraction I and II produced the following readable sequence: Q-T-Q-V-S-N-D-V-V-L-N-D-G-A-S-X-Y-L-N-E-A-L-A (SEQ ID NO: 4), where X stands for an amino acid that cannot be definitely identified, but is most likely either tryptophan or lysine.
  • Ion-spray mass spectral analysis was performed on recombinant DNase B (Example 1) and on Fractions I and II of the purified native DNase B using the Finnigan MAT TSQ 700 triple-stage quadrupole mass spectrometer equipped with the Finnigan Electrospray ionization system. Samples were prepared by reverse phase fractionation using a C4 column as described above. The DNase B proteins eluted at 65% Buffer B and were lyophilized for storage. Prior to injection at a flow rate of 1 ⁇ l/min, the samples were solubilized in acetonitrile-water-acetic acid (50:50:1).
  • the molecular weights determined by mass spectroscopic analysis are as follows: recombinant DNase B (Example 1) -- 25,549; Fraction I of purified natural DNase B -- 25,390; Fraction II of purified natural DNase B -- 25,397. These results are consistent with the nucleotide and amino acid sequencing results, which indicate that the recombinant DNase B has one additional amino acid at the amino terminus.
  • the difference in molecular weights between Fractions I and II of the purified natural DNase B is consistent with a minor modification of an otherwise identical amino acid sequence. A possible modification is deamination, which would cause the appropriate pI shift.
  • the recombinant DNase B protein in the ⁇ DNase B 2-6 phage lysate was identified on an SDS-polyacrylamide gel by Western blot analysis. Rabbit antibody against commercial DNase B was used to detect the presence of recombinant DNase B. Only one protein band was detectable. Coomassie blue staining of an SDS-polyacrylamide gel suggests that the recombinant DNase B protein was about 5% of the total protein in the lysate. Only one nuclease was detected in a SDS-DNA-polyacrylamide gel system. The nuclease has a apparent molecular weight of 25,000 daltons.
  • the purification of the recombinant DNase B protein was monitored using SDS-polyacrylamide gel and a nuclease activity assay using the substrate used for a control in the commercial DNase B assay kit.
  • the purification procedure included: (1) chromatography on Q-sepharose (trimethylaminomethyl agarose); (2) ammonium sulfate precipitation; (3) chromatography on heparin-agarose; and (4) chromatography on Q-sepharose.
  • Two liters of a ⁇ DNase B 2.6 phage lysate was prepared as an overnight culture on Luria broth supplemented with 10 mM MgCl 2 .
  • the supernatant was collected after centrifugation of the culture in a Beckman Instruments (Fullerton, CA) centrifuge at 3635 x g at 4°C for 45 minutes to remove cell debris (the volume of supernatant was 1900 ml).
  • the lysate was filtered through a 0.45 ⁇ m filtration unit to remove residual bacteria and cell debris. This filtrate was then passaged through an approximately 200-ml column of Q-sepharose (Pharmacia, Piscataway, NJ, which had been equilibrated with 20 mM Tris-HCl, pH 7.5, 1 mM EDTA. The flow-through from the column was collected. To this fraction, ammonium sulfate was added slowly to a final concentration of 80% at room temperature to concentrate the lysate. The desalted proteins were centrifuged at 15,000 x g for 30 minutes.
  • Glycerol was added to the dialyzed proteins to a final concentration of 10%. This preparation was filtered through a 0.45 ⁇ m filtration unit. Conductivity of the protein preparation was determined, and the protein preparation was diluted with 20 mM Tris-HCl, pH 7.5, so that the conductivity was the same as that of a solution of 20 mM Tris-pH 7.5, 25 mM NaCl, 10% glycerol (Buffer A). The final volume was 1800 ml.
  • This sample was loaded on to a heparin-sepharose column (approximately 100 ml) on a Pharmacia FPLC system at a flow rate of 120 ml/hr.
  • the column was washed with 400 ml of Buffer A.
  • the DNase B was eluded with one liter of a gradient from 25 mM to 500 mM NaCl in Buffer A.
  • the DNase activity eluted at approximately 125 mM NaCl in a volume of approximately 175 ml.
  • the DNase fraction eluted from the heparin agarose column was dialyzed against 20 mM Tris-HCl, pH 8.5, and was loaded on to an approximately 175-milliliter Q-sepharose column that had been equilibrated in 20 mM Tris-HCl, pH 8.5.
  • the flow-through from the Q-sepharose column was collected and analyzed by isoelectric focusing activity gels, silver staining, and by SDS-polyacrylamide gel electrophoresis.
  • the preparation of recombinant DNase B protein was 99% homogeneous.
  • the protein concentration in the final eluate (110 ml) was about 100 ⁇ g/ml. This is equivalent to a yield of about 5.5 mg/liter of culture.
  • the final product was then subjected to reverse phase high-pressure liquid chromatography, as described above in Example 3.
  • the amino-terminal sequence of purified recombinant DNase B was determined using a Beckman Microsequencing System 2020/Gold.
  • the amino acid sequence was identical to that of natural S. pyogenes DNase B, except that the amino-terminus was arginine (R), and was R-Q-T-Q-V-S-N-D-V-V-L-N-D-G-A-S-K-Y-L-N-E-A-L-A-W-T-F-N-D-S-P-N-Y-Y-K-T-L-G (SEQ ID NO: 6).
  • This arginine arose from the process of producing the recombinant DNase B.
  • oligonucleotides were used as primers in a PCR reaction using the AmpliTaq kit (Perkin-Elmer-Cetus, Norwalk, CT), according to the manufacturer's instructions.
  • the final concentration of MgCl 2 was adjusted to 4 mM, and a 20 cycle reaction was performed (37°C, 2 minutes; 72°C, 3 minutes; 95°C, 2 minutes) using the Perkin-Elmer 480 thermal cycler.
  • DNA of the ⁇ gt 11 clone 2-6 100 ng was used as a template along with 200 ⁇ M of each primer.
  • the resulting amplified product was further digested with Bam HI and Sal I prior to insertion into the ⁇ 33 expression vector.
  • nalidixic acid was added to the inoculated mixture at a final concentration of 60 ⁇ g/ml.
  • the culture was incubated at 37°C for about 8 hours or, alternatively, overnight (approximately 16 hours). All cell fractions were assayed for DNAse B activity including supernatant from the culture, sonicated cell pellets, and supernatants from the sonicated cell pellets.
  • DNAse B was secreted outside the E. coli cells.
  • the 8-hour induction had most of the DNAse B secreted outside the cell, with approximately 30% inside, recovered in the sonicated supernatant.
  • the quantities of DNAse B were great enough to be visualized by Coomassie brilliant blue stain on polyacrylamide gel electrophoresis.
  • a quantity (6 liters) of a recombinant DNAse B clone was grown in superbroth and induced overnight as described in Example 5.
  • the supernatant was harvested and concentrated with a Pellicon concentrator using a 10K membrane; concentration yielded a volume of 600 ml.
  • the concentrated extract was dialyzed against heparin buffer A (20 mM HEPES, pH 7.9, 2 mM dithiothreitol, 10 mM Mg Cl 2 , 0.2 mM EDTA, 0.1 M NaCl, 10% glycerol).
  • the heparin column was loaded, run, and eluted as in Example 3.
  • the eluate from the heparin column was dialyzed in 20 mM ethanolamine, pH 8.5. Small quantities of extraneous proteins were absorbed from the DNAse B preparation by batch absorption onto Q-sepharose.
  • a quantity of Q-sepharose (100 ml) was equilibrated with 20 nM ethanolamine, pH 8.5, and added to 100 ml of the heparin DNAse B fraction.
  • the Q-sepharose was allowed to bind to the extract in a batch procedure for 20 minutes at 4°C. After binding, the Q-sepharose was filtered through a 0.45 ⁇ m filtration unit.
  • the resin was finally washed with 50 ml of 20 mM ethanolamine, pH 8.5 for 20 minutes, prior to separation by centrifugation.
  • the two eluates from this procedure were combined and analyzed by reverse phase chromatography, amino acid sequencing, and mass spectroscopic analysis.
  • reverse phase chromatography 1 ml of the purified DNAse B was passed through a C4 column and eluted at 65% Buffer B in a volume of 1 ml.
  • the same buffers were used as for the purification of the native DNAse B in Example 3.
  • the amino acid sequence was determined using a Beckman Microsequencing System 2020/Gold.
  • the amino acid sequence was R-Q-T-Q-V-S-N-D-V-V-L-N-D-G-A-S-K-Y-L-N-E-A-L-A-W-T-F-N-D-S-P-N-Y-Y-K-T-L-G (SEQ ID NO: 6).
  • the recombinant enzyme is inactivated in an identical manner to the natural S. pyogenes DNase B by human serum containing anti-DNase B enzyme as the result of an immune reaction against naturally occurring S. pyogenes DNase B.
  • Example 4 there was a high level of expression of the DNase B gene from the ⁇ 2-6 clone.
  • an in vitro runoff transcription assay was performed using E. coli RNA polymerase. This assay allows one to determine a precise base of transcriptional initiation by comparing the length of a transcriptional RNA runoff with a Sanger dideoxy sequencing ladder. This assay provides strong evidence for the start site of transcription in E. coli . Comparison with the known transcriptional start sites of a variety of Streptococcus further verifies this site to be the region responsible for streptococcal transcription (J. Ferretti & R. Curtiss, "Streptococcal Genetics” (1987), p. 293 ("Compilation of Nucleotide Sequences that Signal the Initiation of Transcription and Translation in Streptococci”).
  • RNA polymerase recognizes promoter regions and initiates transcription.
  • the enzyme eventually falls off the end of the template, hence this is runoff transcription. This is a standard method for studying transcription start sites.
  • a PCR fragment which includes the upstream region of the DNase B gene was made as a template for an in vitro runoff transcription reaction with E. coli RNA polymerase.
  • E. coli RNA polymerase Using two oligonucleotides, oligonucleotide #246 at positions 298 to 280 and oligonucleotide #267 (not shown in Figure 3), a PCR DNA product of approximately 290 base pairs was made and the fragment was purified after gel electrophoresis.
  • the runoff transcription reaction was performed in 30 mM Tris pH 8, 120 mM KCl, 4 mM MgCl 2 , 10 mM 2-mercaptoethanol, 4 mM spermidine, 0.4 mM ATP, 0.4 mM CTP, 0.4 mM GTP, 0.08 mM UTP, 80 units RNAsin (Promega), 1 unit RNA polymerase (Promega) and 5 ⁇ l [ 32 P] UTP in a total volume of 100 ⁇ l. The mixture was incubated at 37°C for 30 minutes. In order to stop the reaction, 10 ⁇ l of 0.5 M EDTA was added.
  • the sample was diluted and electrophoresed on a sequencing gel.
  • a sequencing reaction using oligonucleotide 246 on 2-6 DNA was performed.
  • the reaction was done using the GIBCO/BRL (Bethesda, MD) cycle sequencing kit.
  • the starting point of the sequencing ladder is the same as the runoff point of the runoff transcript.
  • Figure 7 shows the DNA sequence upstream of the open reading frame and the consensus sequence of an E. coli promoter (D.K. Hawley & W. R. McClure, Nucl. Acids Res. 11:2237-2255 (1983)).
  • the transcription data suggests that there are two possible start sites, position 96 and 97, for RNA polymerase. These sites are marked by an asterisk in Figure 7.
  • the -35 and -10 regions are underlined.
  • Lymphocytes were plated in a microtiter plate (96 Wells) at a concentration of 10 5 cells/well. After three days of growth in a humidified atmosphere: 37°C, 5% CO 2 , with 1 ⁇ Ci of tritiated thymidine (Amersham, Arlington Heights, IL, at 1 mCi/ml) was added to each well. After an additional 24 hours of growth, the cells were transferred to glass tubes using 20 ⁇ l of 100 mM EDTA dissolved in MEM media with 10% fetal bovine serum.
  • TCA trichloroacetic acid
  • the genetic construction described in Examples 5 and 6 produced a recombinant DNase B protein in E. coli which differed from the natural DNase B protein in that the protein was processed at an amino acid one amino acid up from the natural processing site.
  • a genetic construction was made which deletes this "extra" arginine at amino acid 43 (Ala- Arg -Gln-Thr-Gln-Val).
  • This construction was made by using the polymerase chain reaction (PCR) to incorporate modified ends to the DNAase B gene in the ⁇ 2-6 clone.
  • PCR polymerase chain reaction
  • the following oligonucleotides were designed and synthesized on the Pharmacia Gene Assembler Plus DNA synthesizer following the manufacturer's recommendations:
  • oligonucleotides were used as primers in a PCR reaction using the AmpliTaq kit (Perkin-Elmer-Cetus, Norwalk, CT), according to the manufacturer's instructions.
  • the final concentration of MgCl 2 was adjusted to 4 mM, and a 20 cycle reaction was performed (37°C, 2 minutes; 72°C, 3 minutes; 95°C, 2 minutes) using the Perkin-Elmer 480 thermal cycler.
  • DNA of the ⁇ gt11 clone 2-6 100 ng
  • the resulting amplified product was further digested with Bam HI and Sal I prior to insertion into the ⁇ 33 expression vector.
  • nalidixic acid was added to the inoculated mixture at a final concentration of 60 ⁇ g/ml.
  • the culture was incubated at 37°C for about 8 hours or, alternatively, overnight (approximately 16 hours). All cell fractions were assayed for DNase B activity including supernatant from the culture, sonicated cell pellets, and supernatants from the sonicated cell pellets.
  • DNase B was secreted outside the E. coli cell. Quantities of DNase B were enough to be visualized by Coomassie stain, on polyacrylamide gel electrophoresis (PAGE). An IEF (3-9) gel was run, and silver stained. Compared to the previous clone under the pL promotor, there was a clear shift of the pI to the more acidic side.
  • Example 12 Growth and purification of the recombinant DNAse B clone described in Example 12 was performed as described in Example 6.
  • the amino acid sequence was determined using a Beckman Microsequencing System 2020/Gold.
  • the amino acid sequence was determined to be Q-T-Q-V-S-N-D-V-V-L-N-D-G-A-S-K-Y-L-N-E-A-L-A-W-T-F-N-D-S-P-N-Y (SEQ ID NO: 16).
  • This sequence analysis demonstrates that the cleavage product of the arginine deleted construction is identical to the natural DNase B protein produced in Streptococcus pyogenes .
  • Carboxylate latex particles (Interfacial Dynamics Corp.) are coupled to DNase B. The particles are described as high density carboxylate latex particles. The particles typically come in approximately 4% solids in surfactant-free distilled water. Both the 29 nm and the 17 nm diameter particles can be used.
  • Latex particles (5 ml) are diluted 2X with 0.1 M sodium bicarbonate buffer, pH 7.75. On ice, with stirring, the carboxyl groups of the latex particles are activated using a water-soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC). A 20 mg/ml EDAC solution is made and added to the latex particles to a final concentration of 10 mM with constant stirring. After the addition of EDAC, N-hydroxysuccinimide (NHS) (80 mg/ml solution) is added to a final concentration of 70 mM. The latex particle solution turns turbid after the coupling reagents are added. The solution is then stirred for 1 hour on ice.
  • EDAC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • the excess reagents are removed by centrifugation in a Beckman J2-21M, JA 20 rotor at 18,000 rpm for 30 minutes at 10°C. The supernatant is decanted.
  • the latex particles are resuspended in 10 ml of phosphate buffered saline (PBS) containing 1% Tween-20 and 5 mg/ml recombinant DNase B. Small clumps are dispersed with gentle sonication for approximately 1-2 minutes with a Heat Systems-Ultrasonics Inc. sonicator, model W-385. The setting is at 2 using a microtip.
  • the reaction mixture is slightly agitated at room temperature from approximately 20 hours.
  • the unbound DNase B is removed by ultracentrifugation in a Beckman L8-70, Ti60 rotor, at 30,000 rpm for 30 minutes. The supernatant is removed. The latex particles are resuspended in 10 ml of PBS. Small clumps are dispersed by sonication at the same setting as above for approximately 1-2 minutes. The PBS is removed by ultracentrifugation as described above. The washed latex particles are resuspended in 10 mL PBS + 0.01% sodium azide. Alternatively, unbound DNase B can be removed by size exclusion chromatography. The final DNase B latex particle stock (approximately 2%) is stored at 4°C until further dilution for use in an assay.
  • the present invention provides a method of obtaining highly purified S. pyogenes DNase B enzyme without the necessity of growing large quantities of S. pyogenes , an expensive and risky process.
  • the enzyme can be obtained without having to purify it from other proteins of S. pyogenes ; rather, the enzyme can be purified from recombinant phage-infected Escherichia coli or from E. coli transfected with an appropriate expression vector.
  • the expression vector can be chosen so as to optimize expression.
  • the S. pyogenes DNase B can then be used to assay for anti-DNase B antibody in serum in an assay specific for DNase B.
  • an ELISA assay using purified enzyme adsorbed to the solid phase, which is an assay suitable for wide use and easy and convenient to perform.
  • the assay is also of high sensitivity and specificity. Such an assay is particularly suitable for clinical use in detecting S. pyogenes infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

  1. Construction génétique de la séquence d'ADN de la désoxyribonucléase B de Streptococcus pyogenes qui code pour une protéine ayant la séquence d'acides aminés de la figure 4, caractérisée en ce que l'arginine (R) dans la région amino-terminale de ladite protéine est délétée.
  2. Vecteur d'expression pour l'enzyme désoxyribonucléase B de Streptococcus pyogenes comprenant la séquence d'ADN selon la revendication 1 liée de manière opérationnelle à au moins une séquence de contrôle compatible avec une cellule bactérienne hôte appropriée.
  3. Vecteur selon la revendication 2 dans lequel la séquence d'ADN codant l'enzyme désoxyribonucléase B de Streptococcus pyogenes est liée à au moins une séquence d'un bactériophage λ.
  4. Cellule bactérienne hôte transformée à l'aide d'un vecteur d'expression selon la revendication 2 de façon à permettre à la cellule bactérienne hôte transformée d'exprimer la désoxyribonucléase B de Streptococcus pyogenes codée par l'ADN recombinant incorporé dans ledit vecteur d'expression de la revendication 2 en quantité détectable.
  5. Procédé destiné à produire l'enzyme désoxyribonucléase B de Streptococcus pyogenes hautement purifiée, consistant à :
    (a) mettre en culture une cellule bactérienne hôte selon la revendication 4 ;
    (b) utiliser la cellule bactérienne hôte mise en culture pour exprimer l'enzyme désoxyribonucléase B ; et
    (c) purifier l'enzyme à partir de la cellule bactérienne hôte mise en culture.
  6. Fusion transcriptionnelle comprenant la séquence d'ADN recombinante de la désoxyribonucléase B de Streptococcus pyogenes selon la revendication 1 mélangée à un autre gène, dans laquelle la fusion possède une propriété détectable modifiée à partir de la propriété de la séquence selon la revendication 1 ou à partir de la propriété de la protéine codée par la séquence selon la revendication 1, ladite propriété modifiée étant sélectionnée dans le groupe comprenant: (1) un taux élevé d'expression d'ARN ; (2) un taux élevé d'expression de protéine ; (3) une seconde enzyme fonctionnelle, un second récepteur ou une autre protéine active dans la fusion ; (4) une fusion de la désoxyribonucléase B avec un ligand d'affinité ; (5) la production d'une protéine d'un poids moléculaire plus élevé ; et (6) une immunoréactivité accrue.
  7. Fusion traductionnelle comprenant la protéine codée par la séquence d'ADN recombinant de la désoxyribonucléase B de Streptococcus pyogenes selon la revendication 1 mélangée à une autre protéine, dans laquelle la fusion possède une propriété détectable modifiée à partir de la propriété codée par la séquence d'ADN selon la revendication 1, ladite propriété modifiée étant sélectionnée dans le groupe comprenant: (1) un taux élevé d'expression d'ARN ; (2) un taux élevé d'expression de protéine ; (3) une seconde enzyme fonctionnelle, un second récepteur ou une autre protéine active dans la fusion ; (4) une fusion de la désoxyribonucléase B avec un ligand d'affinité ; (5) la production d'une protéine d'un poids moléculaire plus élevé ; et (6) une immunoréactivité accrue.
  8. Procédé destiné à détecter et/ou à déterminer la présence d'un anticorps anti-désoxyribonucléase B de Streptococcus pyogenes dans un échantillon test, comprenant les étapes consistant à :
    (a) lier une enzyme désoxyribonucléase B de Streptococcus pyogenes selon la revendication 4, produite selon le procédé de la revendication 5, à un support solide.
    (b) faire réagir un échantillon test suspecté de contenir un anticorps anti-désoxyribonucléase B de S. pyogenes avec l'enzyme désoxyribonucléase B de S. pyogenes liée au support solide dans le but de lier l'anticorps à l'enzyme et ainsi au support solide ; et
    (c) détecter l'anticorps lié au support solide pour détecter et/ou déterminer la présence d'anticorps dans l'échantillon test.
  9. Procédé destiné à détecter et/ou déterminer la présence d'un anticorps anti-désoxyribonucléase B de Streptococcus pyogenes dans un échantillon test, comprenant les étapes consistant à :
    (a) fournir un échantillon test suspecté de contenir un anticorps anti-désoxyribonucléase B de S. pyogenes ;
    (b) ajouter une quantité de l'enzyme désoxyribonucléase B de S. pyogenes selon la revendication 4, produite selon le procédé de la revendication 5, à l'échantillon test, la quantité étant suffisante pour produire un niveau détectable d'activité enzymatique en l'absence de l'inhibition de l'activité enzymatique par l'anticorps anti-désoxyribonucléase B dans l'échantillon test ; et
    (c) déterminer un niveau d'activité de l'enzyme désoxyribonucléase B dans l'échantillon test en effectuant un dosage enzymatique pour détecter et/ou déterminer la présence de l'anticorps anti-désoxyribonucléase B de S. pyogenes dans l'échantillon test.
  10. Procédé destiné à détecter et/ou déterminer la présence de l'anticorps anti-désoxyribonucléase B de Streptococcus pyogenes dans un échantillon test, comprenant les étapes consistant à :
    (a) préparer une solution tamponnée de l'enzyme désoxyribonucléase B selon la revendication 4, produite selon le procédé de la revendication 5 ;
    (b) faire réagir la solution tamponnée de désoxyribonucléase B avec l'échantillon test suspectée de contenir l'anticorps anti-désoxyribonucléase B de S. pyogenes ; et
    (c) détecter une réaction entre la désoxyribonucléase B et l'anticorps anti-désoxyribonucléase B en observant et/ou en mesurant un changement dans l'absorption de la lumière ou dans la diffusion de la lumière dans la solution.
  11. Vaccin destiné à immuniser un mammifère contre une infection par S. pyogenes comprenant une quantité de désoxyribonucléase B purifiée de S. pyogenes suffisante pour stimuler la production d'anticorps spécifiques à la désoxyribonucléase B de S. pyogenes , dans lequel la désoxyribonucléase B purifiée de S. pyogenes est codée par la séquence d'ADN de la revendication 1.
  12. Vaccin destiné à immuniser un mammifère contre une infection par S. pyogenes comprenant une quantité de désoxyribonucléase B purifiée de S. pyogenes suffisante pour stimuler la production d'anticorps spécifiques à la désoxyribonucléase B de S. pyogenes , dans lequel l'enzyme désoxyribonucléase B purifiée de S. pyogenes est celle qui peut être obtenue par:
    (a) la mise en culture d'une cellule bactérienne hôte transformée grâce à un vecteur d'expression pour l'enzyme désoxyribonucléase B de Streptococcus pyogenes comprenant la séquence d'ADN de la revendication 1, ladite séquence d'ADN étant liée de manière opérationnelle à au moins un séquence de contrôle compatible avec la cellule bactérienne hôte appropriée de façon à permettre à la cellule bactérienne hôte transformée d'exprimer la désoxyribonucléase B de Streptococcus pyogenes codée par l'ADN incorporé dans ledit vecteur d'expression en quantité détectable,
    (b) l'utilisation de la cellule bactérienne hôte mise en culture pour exprimer l'enzyme désoxyribonucléase B ; et
    (c) la purification de l'enzyme à partir de la cellule bactérienne hôte mise en culture.
  13. Vaccin destiné à immuniser un mammifère contre une infection par S. pyogenes comprenant une quantité de désoxyribonucléase B purifiée de S. pyogenes suffisante pour stimuler la production d'anticorps spécifiques à la désoxyribonucléase B de S. pyogenes , dans lequel l'enzyme désoxyribonucléase B purifiée de S. pyogenes est la protéine pouvant être obtenue par l'utilisation de la construction génétique de la revendication 1 dans un vecteur d'expression approprié.
  14. Médicament comprenant une désoxyribonucléase B active sur le plan enzymatique et un moyen de générer un aérosol contenant l'enzyme désoxyribonucléase B active sur le plan enzymatique, destiné à être utilisé dans le traitement de la mucoviscidose chez un patient atteint de mucoviscidose comprenant une libération dudit aérosol en quantité suffisante pour réduire les sécrétions pulmonaires fluides chez le patient, dans lequel l'enzyme désoxyribonucléase B purifiée de S. pyogenes est codée par la séquence d'ADN de la revendication 1.
  15. Médicament comprenant une enzyme désoxyribonucléase B active sur le plan enzymatique et un moyen de générer un aérosol contenant l'enzyme désoxyribonucléase B active sur le plan enzymatique, destiné à être utilisé dans le traitement de la mucoviscidose chez un patient atteint de mucoviscidose comprenant une libération dudit aérosol en quantité suffisante pour réduire les sécrétions pulmonaires fluides chez le patient, dans lequel l'enzyme désoxyribonucléase B purifiée de S. pyogenes est celle pouvant être obtenue par :
    (a) la mise en culture d'une cellule bactérienne hôte transformée grâce à un vecteur d'expression pour la désoxyribonucléase B de Streptococcus pyogenes comprenant la séquence d'ADN de la revendication 1, ladite séquence d'ADN étant liée de manière opérationnelle à au moins un séquence de contrôle compatible avec la cellule bactérienne hôte appropriée de façon à permettre à la cellule bactérienne hôte transformée d'exprimer la désoxyribonucléase B de Streptococcus pyogenes codée par l'ADN incorporé dans ledit vecteur d'expression en quantité détectable,
    (b) l'utilisation de la cellule bactérienne hôte mise en culture pour exprimer l'enzyme désoxyribonucléase B ; et
    (c) la purification de l'enzyme à partir de la cellule bactérienne hôte mise en culture.
EP94927937A 1994-08-18 1994-08-18 ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE Expired - Lifetime EP0726957B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/009450 WO1996006174A1 (fr) 1994-08-18 1994-08-18 ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE

Publications (2)

Publication Number Publication Date
EP0726957A1 EP0726957A1 (fr) 1996-08-21
EP0726957B1 true EP0726957B1 (fr) 2004-11-17

Family

ID=22242885

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94927937A Expired - Lifetime EP0726957B1 (fr) 1994-08-18 1994-08-18 ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE

Country Status (5)

Country Link
EP (1) EP0726957B1 (fr)
JP (1) JP3742896B2 (fr)
AT (1) ATE282701T1 (fr)
DE (1) DE69434135T2 (fr)
WO (1) WO1996006174A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102183636A (zh) * 2010-12-30 2011-09-14 王滔 抗a族链球菌dna酶b抗体化学发光法诊断试剂盒及其使用方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2477914B (en) * 2010-02-12 2012-01-04 Univ Newcastle Compounds and methods for biofilm disruption and prevention

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3637253A1 (de) * 1986-11-03 1988-05-05 Behringwerke Ag Latex-agglutinations-verfahren zum nachweis von anti-streptokokken-desoxyribonuclease b
EP0613947B1 (fr) * 1993-02-01 2004-03-03 Beckman-Coulter, Inc. Facteur mitogénique, son gène et méthode pour sa microdetection
DE69433107T2 (de) * 1993-06-23 2004-07-08 Beckman Coulter, Inc., Fullerton Rekombinante dnase b aus streptococcus pyogenes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102183636A (zh) * 2010-12-30 2011-09-14 王滔 抗a族链球菌dna酶b抗体化学发光法诊断试剂盒及其使用方法

Also Published As

Publication number Publication date
DE69434135D1 (de) 2004-12-23
DE69434135T2 (de) 2005-12-01
WO1996006174A1 (fr) 1996-02-29
EP0726957A1 (fr) 1996-08-21
JPH09504962A (ja) 1997-05-20
JP3742896B2 (ja) 2006-02-08
ATE282701T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
US6420152B1 (en) Recombinant DNase B derived from Streptococcus pyogenes
JP2614176B2 (ja) 連鎖球菌ｍ蛋白免疫原の製造方法
US5004692A (en) Cloning and expression of phosopholipase C genes
US4599305A (en) Method and composition for detection of human chronic myelogenous leukemia
JP2001504684A (ja) 髄膜炎菌種の細菌に特異的なｄｎａおよび蛋白質またはペプチド、それらの取得方法およびそれらの生物学的応用
JPH03504077A (ja) ライグラス花粉アレルゲン
US5707822A (en) Gene serum opacity factor
EP1141308B1 (fr) Genes et proteines de streptococcus du groupe b, et leur utilisation
GB2233977A (en) Cysteine-free streptolysin O
Malke Cytoplasmic membrane lipoprotein LppC of Streptococcus equisimilis functions as an acid phosphatase
AU714435B2 (en) Methods and compositions for identifying streptococcus containing a cysteine protease or fragment thereof
US7005510B1 (en) Recombinant DNase B derived from Streptococcus pyogenes
US5695956A (en) Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent
CA1335800C (fr) Phospholipases synoviales
Collier Inhibition of protein synthesis by exotoxins from Corynebacterium diphtheriae and Pseudomonas aeruginosa
EP0726957B1 (fr) ADNase B RECOMBINANTE DERIVEE DE PYOGENES DE STREPTOCOQUE
JPH10113189A (ja) 新規 ＲＮａｓｅＰ
KR20010099885A (ko) 외표면 단백질들, 그들의 유전자들 및 그들의 사용
CA2174534A1 (fr) Adnase b recombinante derivee de pyogenes de streptocoque
JPH04144686A (ja) 構造蛋白質遺伝子、組換えベクター、それにより形質転換された大腸菌、ポリペプチドおよびポリペプチドの製造方法
AU753045B2 (en) Methods and compositions for identifying streptococcus containing a cysteine protease or fragment thereof
AU704745B2 (en) Gene serum opacity factor
WO2001002577A1 (fr) Antigenes de pseudomonas aeruginosa
KR20010012096A (ko) 스트렙토콕커스 뉴모니애로부터의 사람 보체 ｃ3-분해 프로테이나아제
JP2002525048A (ja) Ｒｎａｓｅｐポリペプチド

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19960819

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BECKMAN COULTER, INC.

17Q First examination report despatched

Effective date: 20010509

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041117

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041117

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20041117

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041117

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041117

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041117

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69434135

Country of ref document: DE

Date of ref document: 20041223

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050217

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050217

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050228

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20050803

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050818

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050818

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050818

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050417

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20070830

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20071001

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20070817

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20080818

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20090430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080901

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080818